PET for Drug Development and Evaluation

Front Matter....Pages i-viii
Drug Development and Positron Emission Tomography....Pages 1-24
Positron Emission Tomography: Basic Principles and Potential Interest for Pharmacological Studies....Pages 25-35
Is PET a Tool for Drug Evaluation?....Pages 37-50
PET in Neuropsychiatric Drug Development....Pages 51-53
Radioligand Disposition and Metabolism — Key Information in Early Drug Development....Pages 55-65
PET Studies in the Early Clinical Development of a New Antipsychotic....Pages 67-71
PET in the Development of Dopamine D1 Antagonists as New Potential Antipsychotic Drugs....Pages 73-81
Is the 5-HT 2 -Receptor a Target for Antipsychotic Drug Action? PET Studies on Dopamine (D 2 and Serotonin (5-HT 2 ) Receptor Occupancy in Patients and Healthy Subjects....Pages 83-92
Preclinical Development of a Radioligand for the Study of Central 5-HT 1A Receptors with PET — [ 11 C]Way-100635....Pages 93-108
Comparative In vivo and In vitro Selectivity of Zolpidem for ω (Benzodiazepine) Modulatory Site Subtypes....Pages 109-122
Do the Effects of Muscarinic Receptor Blockade on Brain Glucose Consumption Mimic the Cortical and Subcortical Metabolic Pattern of Alzheimer’s Disease in Normal Volunteers ?....Pages 123-132
PET Evaluation of Drug Treatment in Ischemic Stroke and Alzheimer’s Disease....Pages 133-146
PET Imaging of Cerebral Perfusion and Oxygen Metabolism in Acute Ischemic Stroke: Implications for Management and Therapy....Pages 147-154
Pharmacokinetics: Kinetic Modelling of MAO Inhibitors and D 2 Antagonists....Pages 155-165
Brain Activation Under Drug Treatment....Pages 167-177
Modifying the Progression of Parkinson’s Disease....Pages 179-188
COMT Inhibition: Pharmacology of Tolcapone and 6-[ 18 F]-Fluoro-L-DOPA (FDOPA) PET Results....Pages 189-195
Interaction of Lisuride with dopaminergic receptors....Pages 197-203
Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site....Pages 205-214
Drug Design in Cardiology: The Pharmaceutical Industry Point of View....Pages 215-218
Myocardial Receptors and Their Interaction with Cardiovascular Drugs....Pages 219-231
The Pathophysiological Background of Cardiovascular Diseases and its Impact on Diagnosis and Treatment....Pages 233-251
Effect of Cardiotonic Drugs on Myocardial Oxygen Consumption and Efficiency as Assessed by 11 C-Acetate and PET....Pages 253-262
Integration of New and Classical Techniques in Drug Development. PET Application to Propionyl-L-Carnitine Pharmacokinetic Study....Pages 263-266
The View of the EORTC New Drug Development Office on PET in (Pre)Clinical Trials of Anticancer Drugs....Pages 267-275
Bottlenecks in Anticancer Drug Discovery and Development: In vivo Pharmacokinetic and Pharmacodynamic Issues and the Potential Role of PET....Pages 277-285
Radiolabelled Anticancer Drugs for In vivo Pharmacokinetic Studies by PET....Pages 287-300
The Use of Radiolabelled Anticancer Drugs in Phase I/II Clinical Trials and the Assessment of Therapeutic Efficacy of New Agents Using PET....Pages 301-326
Kinetics and Applications of F-18-Fluorouracil in Colorectal Tumors....Pages 327-339
The Disposition of a New Drug Propellant (HFA 134a) in Humans Studied by Fluorine-18 Labelling and Whole-Body γ-Counting....Pages 341-352
Preclinical Characterisation of Radiolabelled Idoxifene....Pages 353-360